MedTrace Logo

Prospective Electronic Polygenic Risk Study - Second Phase

NCT05175651 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10000

Last updated 2022-11-07

No results posted yet for this study

Summary

This study will investigate the role of polygenic risk scores (PRS) in preventive health.

Conditions

Interventions

BEHAVIORAL

Genetic risk assessment

A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.

Sponsors & Collaborators

  • Illumina, Inc.

    collaborator INDUSTRY

  • Optum, Inc.

    collaborator INDUSTRY

  • Quest Diagnostics-Nichols Insitute

    collaborator INDUSTRY

  • Scripps Translational Science Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2025-01-15
Completion
2027-01-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05175651 on ClinicalTrials.gov